Aditxt Inc (ADTX) Stock Analysis

Verdict: AVOID

Terminal-stage biotech with negligible revenue ($3k) and catastrophic cash burn faces imminent insolvency and total equity wipeout.

Investment score: 3/100

Analysis as of

Is Aditxt Inc stock worth reviewing? AI model thesis

Aditxt is a micro-cap biotech in a severe financial crisis. It lacks the revenue to sustain operations, suffers from extreme dilution, and exhibits 'meme-stock' volatility that is disconnected from its near-zero fundamental value.

7-factor investment score

Aditxt Inc opportunities and risks

What speaks for ADTX

What speaks against ADTX

Peers and competitors

Trailing-twelve-month ratios
TickerP/EP/SEV/EBITDAGross marginNet marginFCF yield
ADTXn/a0.0xn/a19.9%-362385.7%-5842076.1%
INTSn/a0.0x0.3x0.0%0.0%-119.0%
BCLIn/a0.0xn/a0.0%0.0%-63.9%
BRTXn/a9.8xn/a92.1%-3089.6%-339.2%
AIMn/a12.7x0.0x-133.0%-14123.4%-973.0%
APREn/a43.2x3.5x-1523.6%-10121.7%-239.6%
Peer mediann/a9.8x0.0x0.0%-3089.6%-239.6%

Frequently asked questions about Aditxt Inc (ADTX)

Is ADTX stock a good investment?

The cached TradeMates AI model rates Aditxt Inc as AVOID with an investment score of 3/100. Aditxt is a micro-cap biotech in a severe financial crisis. It lacks the revenue to sustain operations, suffers from extreme dilution, and exhibits 'meme-stock' volatility that is disconnected from its near-zero fundamental value. This is algorithmic model output, not personal investment advice.

Is ADTX stock a buy?

The TradeMates model verdict for ADTX is AVOID with an investment score of 3/100. Treat this as a model signal to review, not a personal buy recommendation.